Jan Naseer Kaur

Dr. Jan Naseer Kaur

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JKJan Naseer Kaur
Jan Naseer Kaur
NSNavaldeep Singh
Navaldeep Singh
NSNicholas M. Smith
Nicholas M. Smith
JKJack F. Klem
Jack F. Klem
RCRaymond Cha
Raymond Cha
BTBrian T. Tsuji
Brian T. Tsuji
Antimicrobial resistance has emerged as one of the leading public health threats of the twenty-first century. Gram-negative pathogens have been a major contributor to the declining efficacy of antibiotics through both acquired resistance and tolerance. In this study, a pan-drug resistant (PDR), NDM-1 and CTX-M-15 co-producing isolate of K. pneumoniae, CDC Nevada, (Kp Nevada) was exposed to the clinical combination of aztreonam + ceftazidime/avibactam (ATM/CAZ/AVI) to overcome metallo-β-lactamases. Unexpectedly, the β-lactam combination resulted in long filamentous cell formation induced by PBP3 inhibition over 168 h in the hollow fiber infection model experiments with eventual reversion of the total population upon drug removal. However, the addition of imipenem to the two drug β-lactam combination was highly synergistic with suppression of all drug resistant subpopulations over 5 days. Scanning electron microscopy and fluorescence microscopy for all imipenem combinations in time kill studies suggested a role for imipenem in suppression of long filamentous persisters, via the formation of metabolically active spheroplasts. To complement the imaging studies, salient transcriptomic changes were quantified using RT-PCR and novel cassette assay evaluated β-lactam permeability. This showed significant upregulation of both spheroplast protein Y (SPY), a periplasmic chaperone protein that has been shown to be related to spheroplast formation, and penicillin binding proteins (PBP1, PBP2, PBP3) for all combinations involving imipenem. However, with aztreonam alone, pbp1, pbp3 and spy remained unchanged while pbp2 levels were downregulated by > 25%. Imipenem displayed 207-fold higher permeability as compared with aztreonam (mean permeability coefficient of 17,200 nm/s). Although the clinical combination of aztreonam/avibactam and ceftazidime has been proposed as an important treatment of MBL Gram-negatives, we report the first occurrence of long filamentous persister formation. To our knowledge, this is the first study that defines novel β-lactam combinations involving imipenem via maximal suppression of filamentous persisters to combat PDR CDC Nevada K. pneumoniae.

21 December 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
NSNicholas Smith
Nicholas Smith
TNThomas D. Nguyen
Thomas D. Nguyen
TLthomas patrick lodise
thomas patrick lodise
LCLiang Chen
Liang Chen
JKJan Naseer Kaur
Jan Naseer Kaur
BTBrian T. Tsuji
Brian T. Tsuji

8 October 2024 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
JKJan Naseer Kaur
Jan Naseer Kaur
JKJack F Klem
Jack F Klem
YLYang Liu
Yang Liu
KBKatie Rose Boissonneault
Katie Rose Boissonneault
PHPatricia N Holden
Patricia N Holden
BTBrian T. Tsuji
Brian T. Tsuji
Gram-negatives harboring metallo-β-lactamases (MBLs) and extended-spectrum β-lactamases (ESBLs) pose a substantial risk to the public health landscape. In ongoing efforts to combat these “superbugs,” we explored the clinical combination of aztreonam and ceftazidime/avibactam together with varying dosages of polymyxin B and imipenem against Klebsiella pneumoniae ( Kp CDC Nevada) in a 9-day hollow fiber infection model (HFIM). As previously reported by our group, although the base of aztreonam and ceftazidime/avibactam alone leads to 3.34 log 10 fold reductions within 72 hours, addition of polymyxin B or imipenem to the base regimen caused maximal killing of 7.55 log 10 and 7.4 log 10 fold reduction, respectively, by the 72-hour time point. Although low-dose polymyxin B and imipenem enhanced the bactericidal activity as an adjuvant to aztreonam +ceftazidime/avibactam, regrowth to ~9 log 10 CFU/mL by 216 hours rendered these combinations ineffective. When aztreonam +ceftazidime/avibactam was supplemented with high-dose polymyxin B and or low-dose polymyxin B + imipenem, it resulted in effective long-term clearance of the bacterial population. Time lapse microscopy profiled the emergence of long filamentous cells in response to PBP3 binding due to aztreonam and ceftazidime. The emergence of spheroplasts via imipenem and damage to the outer membrane via polymyxin B was visualized as a mechanism of persister killing. Despite intrinsic mgrB and bla NDM-1 resistance, polymyxin B and β-lactam combinations represent a promising strategy. Future studies using an integrated molecularly precise pharmacodynamic approach are warranted to unravel the mechanistic details to propose optimal antibiotic combinations to combat untreatable, pan-drug-resistant Gram-negatives.

27 November 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
JKJack F Klem
Jack F Klem
PCPharm D Candidate
Pharm D Candidate
JKJan Naseer Kaur
Jan Naseer Kaur
NSNicholas Smith
Nicholas Smith
ACAl Chen
Al Chen
BTBrian T. Tsuji
Brian T. Tsuji
‘Nightmare’ MBL gram-negatives resistant to nearly all antibiotics have emerged in the clinical setting and are a cause for concern. Here, we assessed the role of targeted PBP2 binding using mecillinam (MEC), which is currently available in other countries and has high affinity for PBP2, as an adjuvant to established β-lactam regimens to combat pan drug resistance. Klebsiella pneumoniae harboring blaNDM-1, blaCMY-6, blaCTX-M-15, and blaSHV-2 was exposed to an array of therapeutic drug regimens in a Hollow Fiber Infection Model (HFIM) at a starting inoculum of ∼107 CFU/mL over 168h. These arms included MEC monotherapy (2hPI Q8H, target Cmax,ss = 32 ug/mL) in addition to combination regimens that contained aztreonam (ATM) (2g 2hPI Q8H) + ceftazidime/avibactam (CAZ/AVI) (2g/0.5g 2hPI Q8H) ± MEC (2hPI Q8H, target Cmax,ss = 32 ug/mL). All drugs were discontinued at 168h, after which populations were assessed for regrowth for 48h. Samples were also collected, fixed, and imaged under a scanning electron microscope (SEM, Carl Zeiss Auriga). The MEC monotherapy arm regrew to carrying capacity (∼1010 CFU/mL) in 24h whereas combination arms demonstrated bactericidal activity throughout the duration of drug treatment. While 24h killing rates were comparable between the two combination arms, 168h counts were ∼3.0 log10 CFU/mL lower in ATM + CAZ/AVI + MEC than in ATM + CAZ/AVI (102.90 CFU/mL vs. 105.92 CFU/mL, respectively). Both combination arms recovered following drug discontinuation; however, this recovery was delayed in ATM + CAZ/AVI + MEC as was supported by a ∼6.5 log10 CFU/mL difference in 192h counts (109.51 CFU/mL in ATM + CAZ/AVI vs. 102.98 CFU/mL in ATM + CAZ/AVI + MEC). 192h SEMs supported this observation as rods predominated in the ATM + CAZ/AVI sample whereas more debris/fewer cells were apparent in the ATM + CAZ/AVI + MEC sample. Spheroplasts were observed throughout drug treatment in all samples treated with MEC. The targeted PBP2 binding capacity of MEC may be a promising adjuvant to β-lactam/β-lactamase inhibitor combinations. Non-traditional β-lactam strategies that enhance the existing antibiotics may be of paramount importance for clinicians to combat MBL gram negative pan drug resistance. All Authors: No reported disclosures

11 October 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JKJan Naseer Kaur
Jan Naseer Kaur
JKJack F. Klem
Jack F. Klem
GHGebremedhin Solomon Hailu
Gebremedhin Solomon Hailu
NNNader N. Nasief
Nader N. Nasief
YLYang Liu
Yang Liu
BTBrian T. Tsuji
Brian T. Tsuji
Background: The emergence of pan-drug-resistant (PDR) Klebsiella pneumoniae has compromised the efficacy of last-line agents, leaving few therapeutic options. Repurposing zidovudine, an FDA-approved thymidine analog with antibacterial activity, may enhance existing therapies, but pharmacodynamic data under clinically relevant conditions are scarce. This study addresses this gap using static and dynamic in vitro models. Materials/methods: A PDR strain of Klebsiella pneumoniae harboring blaNDM-1, blaCMY-6, blaCTX-M-15, blaSHV-2, and disrupted mgrB was used in this study. Minimum inhibitory concentrations (MICs) followed by static time-kills were performed to investigate the synergistic interplay between zidovudine and last-line antibiotics (ceftazidime/avibactam, polymyxin B). To simulate human pharmacokinetics, a hollow-fiber infection model (HFIM) was employed using steady-state concentrations of zidovudine (4 mg/L), polymyxin B (4 mg/L), and avibactam (22 mg/L). Structural and morphological effects on bacterial cells were examined via fluorescence microscopy following glutaraldehyde fixation. Results: In this study, the PDR K. pneumoniae showed a ~5-fold reduction in polymyxin MIC when combined with zidovudine (from >4 µg/mL to 0.25 µg/mL). Time-kill assays demonstrated ≥2.5 log10 CFU/mL bacterial reduction with zidovudine-based combinations, whereas monotherapies failed to inhibit bacterial growth. In the HFIM, the triple combination achieved rapid bactericidal activity (>3 log10 CFU/mL reduction within 4 h) and sustained killing (>5–6 log10 reduction maintained through 216 h), with bacterial counts remaining below 1 CFU/mL. In contrast, dual combinations initially reduced bacterial burden (1–3 log10 reduction) but failed to maintain suppression, with significant regrowth (>1010 CFU/mL) observed by 168 h. Microscopy corroborated these findings, revealing extensive cellular damage in the zidovudine-containing treatment arms. These HFIM results underscore the potential of zidovudine-based triple therapy in overcoming resistance to last-line antibiotics in K. pneumoniae. Conclusions: Our results provide promising unprecedented insight into novel zidovudine-based combination therapies against difficult-to-treat MBL Gram-negatives. The observed synergy in MIC reduction, rapid killing in time-kill assays, and near-complete eradication in the HFIM underscore the therapeutic potential of this triple combination. Future studies will focus on broadening the application of these novel combinations to other ‘superbugs’, such as highly resistant strains of Acinetobacter baumannii and Pseudomonas aeruginosa.

7 April 2026 in Microbiology Spectrum
Verified
Journal Article
Open access
MKMurat C. Kalem
Murat C. Kalem
SDSean Duffy
Sean Duffy
ABAmanda L. M. Bloom
Amanda L. M. Bloom
SSShichen Shen
Shichen Shen
JKJan Naseer Kaur
Jan Naseer Kaur
JPJohn Panepinto
John Panepinto
The evolutionarily conserved Pumilio domain-containing RNA binding proteins (RBPs) are involved in many steps of post-transcriptional gene regulation, including RNA stability, polyadenylation, deadenylation, and translation. Most RBPs are post-translationally modified by methylation of arginine/glycine-rich domains (RG-box) though the consequences of these modifications are not well known. We determined the arginine methylation and phosphorylation landscape of the Pumilio domain containing RBP Puf4 from the basidiomycete fungus Cryptococcus neoformans . We found that methyl-deficient Puf4 mutants do largely complement critical PUF4 deletion phenotypes, such as resistances to endoplasmic reticulum stress, antifungals, and thermotolerance, but were unable to complement the melanization defect of the puf4 △ mutant. Analysis of the Puf4 interactome revealed temperature-dependent and -independent protein-protein interactions, some of which were altered by the methyl-deficient mutations. Overall, we show that the RNA-binding protein Puf4 exhibits extensive post-translational modifications, particularly arginine methylation that impacts function and protein-protein interactions. IMPORTANCE: Post-transcriptional processes play a crucial role in modulating responses to various stressors, including temperature and antifungals. To ensure adaptation and survival, stressors must be accurately sensed, and responses tightly regulated. Post-translational modifications serve as a crucial regulatory layer that orchestrates nuanced stress responses. We highlight extensive methylation and phosphorylation of the RNA-binding protein Puf4 and explore the regulatory roles of select methylated arginines. We also found that the interactome network of Puf4 varies with temperature. Cryptococcus neoformans, a basidiomycete fungus that is also an important human pathogen, is an ideal system to illustrate the evolution of gene regulatory processes and how these kingdom or clade-specific regulatory modules contribute to the pathogenic potential of fungi.